Thursday, April 10, 2014 8:55:15 AM
http://seekingalpha.com/article/2132353-navidea-continues-to-execute-when-will-the-stock-follow
Summary
•Lymphoseek continues to gain new market opportunities.
•Oxford loan enhances financial flexibility.
•Short interest has been trending down.
•However, gains in the stock price itself continue to be elusive.
To be blunt, Navidea Biopharmaceuticals (NAVB) has been a poor performer over the past year. Furthermore, anyone who reasoned as I did and saw the share price movement following the Crede financing deal last October as a buying opportunity, is likely looking at a loss now unless the managed to buy near the bottom. Pro subscribers can see the article here....more
..
Lymphoseek on Track to Take Market Share
Since receiving a temporary CMS reimbursement pass through C-code on October 1st last year, sales of Lymphoseek (LS) have begun to ramp up nicely. President and Chief Business Officer Dr. Thomas H. Tulip noted on the Q4 2013 conference call that 80% of customers have reordered and had this reassurance about market penetration rates:
“
I've looked for comparisons and found a few innovative premium price therapeutics launched in recent years[.]... The very best disease launches leading to very substantive sales of well-known products did not exceed 10% market share after the first year on the market. So Lymphoseek compares well as we will certainly get beyond 10% penetration in the first year.
This, along with the reiterating the projection for LS to reach a majority market share within 10 to 14 months....more...
..
I have long since given up on trying to time this stock or offer short term guidance, but Navidea continues to execute very well in my opinion. Hopefully, someday in the not-too-distant future, its stock will reflect that
Recent NAVB News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/21/2023 08:32:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 11:26:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 04:49:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:55:52 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 10/23/2023 05:56:24 PM
- Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock • Business Wire • 10/06/2023 01:01:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/05/2023 08:21:49 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/15/2023 07:42:35 PM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM